Clinical Trials Browser

Phase 1 × osimertinib × Endocrine × Clear all

NCT05142189 2026-04-14

LuCa-MERIT-1

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a